Investigation of the activity of baicalein towards Zika virus.
Antiviral activity
Baicalein
Half-maximal effective concentration
Zika virus
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
03 May 2023
03 May 2023
Historique:
received:
22
04
2022
accepted:
24
04
2023
medline:
5
5
2023
pubmed:
4
5
2023
entrez:
3
5
2023
Statut:
epublish
Résumé
Zika virus (ZIKV) is a mosquito transmitted virus spread primarily by Aedes species mosquitoes that can cause disease in humans, particularly when infection occurs in pregnancy where the virus can have a significant impact on the developing fetus. Despite this, there remains no prophylactic agent or therapeutic treatment for infection. Baicalein is a trihydroxyflavone, that is found in some traditional medicines commonly used in Asia, and has been shown to have several activities including antiviral properties. Importantly, studies have shown baicalein to be safe and well tolerated in humans, increasing its potential utilization. This study sought to determine the anti-ZIKV activity of baicalein using a human cell line (A549). Cytotoxicity of baicalein was determined by the MTT assay, and the effect on ZIKV infection determined by treating A549 cells with baicalien at different time points in the infection process. Parameters including level of infection, virus production, viral protein expression and genome copy number were assessed by flow cytometry, plaque assay, western blot and quantitative RT-PCR, respectively. The results showed that baicalein had a half-maximal cytotoxic concentration (CC Baicalein has now been shown to possess anti-ZIKV activity in a human cell line.
Sections du résumé
BACKGROUND
BACKGROUND
Zika virus (ZIKV) is a mosquito transmitted virus spread primarily by Aedes species mosquitoes that can cause disease in humans, particularly when infection occurs in pregnancy where the virus can have a significant impact on the developing fetus. Despite this, there remains no prophylactic agent or therapeutic treatment for infection. Baicalein is a trihydroxyflavone, that is found in some traditional medicines commonly used in Asia, and has been shown to have several activities including antiviral properties. Importantly, studies have shown baicalein to be safe and well tolerated in humans, increasing its potential utilization.
METHODS
METHODS
This study sought to determine the anti-ZIKV activity of baicalein using a human cell line (A549). Cytotoxicity of baicalein was determined by the MTT assay, and the effect on ZIKV infection determined by treating A549 cells with baicalien at different time points in the infection process. Parameters including level of infection, virus production, viral protein expression and genome copy number were assessed by flow cytometry, plaque assay, western blot and quantitative RT-PCR, respectively.
RESULTS
RESULTS
The results showed that baicalein had a half-maximal cytotoxic concentration (CC
CONCLUSION
CONCLUSIONS
Baicalein has now been shown to possess anti-ZIKV activity in a human cell line.
Identifiants
pubmed: 37138273
doi: 10.1186/s12906-023-03971-4
pii: 10.1186/s12906-023-03971-4
pmc: PMC10158012
doi:
Substances chimiques
baicalein
49QAH60606
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
143Subventions
Organisme : National Research Council of Thailand and Mahidol University
ID : NRCT5-RSA63015-03
Organisme : Mahidol University
ID : NDFR 28/2564
Organisme : Thailand Graduate Institute of Science and Technology
ID : SCA-CO-2561-6984TH
Organisme : Thailand Graduate Institute of Science and Technology
ID : TG-22-14-59-005D
Organisme : Thailand Research Fund
ID : IRN5802PHDW04 under IRN58W0002
Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2014 Jun 26;4:5452
pubmed: 24965553
J Neurosci Res. 2013 Sep;91(9):1239-46
pubmed: 23686791
Clin Transl Oncol. 2020 Jul;22(7):1013-1022
pubmed: 31650468
Sci Bull (Beijing). 2016;61(18):1391-1398
pubmed: 27730005
Euro Surveill. 2014 Jan 30;19(4):
pubmed: 24507466
Arch Virol. 2011 May;156(5):793-801
pubmed: 21286764
J Pharm Sci. 2006 Jun;95(6):1326-33
pubmed: 16628739
Nat Ecol Evol. 2019 Apr;3(4):561-569
pubmed: 30886369
Lancet Infect Dis. 2016 Jul;16(7):e119-e126
pubmed: 27282424
Euro Surveill. 2014 Mar 06;19(9):
pubmed: 24626205
Pathog Glob Health. 2021 Feb;115(1):21-39
pubmed: 33191867
Drug Des Devel Ther. 2016 Jan 07;10:183-203
pubmed: 26792984
Eur J Biochem. 1990 Jul 5;190(3):469-76
pubmed: 1695572
N Engl J Med. 2016 Mar 10;374(10):951-8
pubmed: 26862926
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
Biomed Pharmacother. 2017 Jun;90:677-685
pubmed: 28415048
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
Int J Mol Sci. 2012 Dec 07;13(12):16785-95
pubmed: 23222683
Lancet Infect Dis. 2016 Aug;16(8):894-5
pubmed: 27477981
Immunity. 2005 Jul;23(1):19-28
pubmed: 16039576
Cell Host Microbe. 2016 May 11;19(5):561-5
pubmed: 27091703
Lancet Infect Dis. 2017 Jan;17(1):15-17
pubmed: 27998553
Molecules. 2018 Jan 20;23(1):
pubmed: 29361712
PLoS One. 2016 Apr 29;11(4):e0153468
pubmed: 27128436
J Ethnopharmacol. 2015 Feb 23;161:255-78
pubmed: 25543018
Mem Inst Oswaldo Cruz. 2015 Jun;110(4):569-72
pubmed: 26061233
Phytother Res. 2014 Sep;28(9):1342-8
pubmed: 24596136
Emerg Infect Dis. 2017 May;23(5):841-845
pubmed: 28277198
Emerg Infect Dis. 2011 May;17(5):880-2
pubmed: 21529401
J Immunol Methods. 2007 Jan 10;318(1-2):11-9
pubmed: 17141265
Lancet Infect Dis. 2016 Apr;16(4):405
pubmed: 26949027
Emerg Infect Dis. 2014 Jun;20(6):1085-6
pubmed: 24856001
Int J Oncol. 2018 Aug;53(2):750-760
pubmed: 29749481
Lancet. 2016 Aug 27;388(10047):891-7
pubmed: 27372398
Clin Drug Investig. 2016 Sep;36(9):713-724
pubmed: 27352310
Emerg Infect Dis. 2008 Aug;14(8):1232-9
pubmed: 18680646
Lancet. 2016 Jan 23;387(10016):335-336
pubmed: 26777915
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
BMC Complement Altern Med. 2012 Nov 09;12:214
pubmed: 23140177
Emerg Infect Dis. 2014 Aug;20(8):1412-4
pubmed: 25062427
Euro Surveill. 2014 Apr 03;19(13):
pubmed: 24721538
Molecules. 2020 Mar 10;25(5):
pubmed: 32164193
Aging (Albany NY). 2019 Nov 6;11(21):9310-9327
pubmed: 31692453
Antiviral Res. 2011 Sep;91(3):314-20
pubmed: 21782851
Virol J. 2017 Feb 13;14(1):28
pubmed: 28193229
Trans R Soc Trop Med Hyg. 1964 Jul;58:335-8
pubmed: 14175744
Virology. 2019 Jul;533:59-67
pubmed: 31112915
Toxicol Ind Health. 2012 Jun;28(5):412-21
pubmed: 21957089
Antiviral Res. 2016 Sep;133:50-61
pubmed: 27460167
Am J Trop Med Hyg. 2015 Aug;93(2):380-383
pubmed: 26101272
Comput Biol Chem. 2018 Dec;77:402-412
pubmed: 30471642
Viruses. 2021 May 12;13(5):
pubmed: 34066055
Arch Virol. 2007;152(4):687-96
pubmed: 17195954
J Pharm Biomed Anal. 2005 Mar 9;37(3):535-41
pubmed: 15740914
Nat Commun. 2017 Feb 21;8:14575
pubmed: 28220786
Mol Cells. 2001 Aug 31;12(1):127-30
pubmed: 11561722
Oncol Res. 2018 May 7;26(4):645-653
pubmed: 28835320
Arch Virol. 2019 Feb;164(2):585-593
pubmed: 30392049
Emerg Infect Dis. 2015 Oct;21(10):1885-6
pubmed: 26401719
Am J Trop Med Hyg. 1982 Jul;31(4):830-6
pubmed: 6285749
Euro Surveill. 2014 Apr 10;19(14):
pubmed: 24739982
Arch Biochem Biophys. 2019 Oct 30;675:108119
pubmed: 31568753
Arch Virol. 2023 Jan 7;168(2):47
pubmed: 36609616
J Cell Mol Med. 2018 Apr;22(4):2478-2487
pubmed: 29392841
J Virol. 1998 Jan;72(1):73-83
pubmed: 9420202
Biochim Biophys Acta. 2016 Oct;1862(10):1883-90
pubmed: 27425033
Antiviral Res. 2018 Feb;150:101-111
pubmed: 29269135
J Ethnopharmacol. 2014 Oct 28;156:210-5
pubmed: 25219601
Sci Rep. 2020 Jan 30;10(1):1499
pubmed: 32001767
PLoS Negl Trop Dis. 2012;6(2):e1477
pubmed: 22389730